Abstract
Several lines of evidence have suggested a link between serotonergic and dopaminergic systems in the brain. The interpretation of much of these early data needs careful reevaluation in light of the recent understanding of the plethora of serotonin receptor subtypes, their distribution in the brain and the new findings with more selective serotonin antagonists. Electrophysiological, biochemical and behavioral evidence obtained using highly selective antagonists of the 5-HT2 or 5-HT3 receptor subtypes, MDL 100,907 or MDL 73,147EF, respectively, supports the thesis that serotonin modulates the dopaminergic system. This modulation is most evident when the dopaminergic system has been activated.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bradford MM (1976) A rapid and sensitive model for the quantification of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248–254
Braestrup C, Squires RF (1978) Pharmacological characterization of benzodiazepine receptors in the brain. Eur J Pharmacol 48:263–270
Carr AA, Hay DA, Dudley MW, Kehne JH, Nieduzak TR (1990) Derivatives of MDL 11,939 as highly potent and selective inhibitors of serotonin 5-HT2 receptors. Presented at the Second IUPHAR Serotonin Satellite Meeting, Basel, Switzerland, July 11–13
Chang RSL, Tran VT, Snyder SH (1978) Histamine H1 receptors in brain labelled with [3H]mepyranine. Eur J Pharmacol 48:463–464
Cheng YC, Prusoff WH (1973) Relationship between inhibition constant (Ki) and the concentration of inhibitor which causes 50% inhibition (I50) of an enzyme reaction. Biochem Pharmacol 22:3099–3108
Cheung Y, Bennett DB, Nahorski SR (1985) [3H]Rauwolscine and [3H]yohimbine to rat cerebral and human platelet membranes: possible heterogeneity of α2-adrenoceptors. Eur J Pharmacol 84:79–85
Creese I, Schneider R, Snyder SH (1977) [3H]-Spiroperidol labels dopamine receptors in the pituitary and brain. Eur J Pharmacol 46:377–381
DeFeudis FS, Ossola L, Schmitt G, Wolff P, Mandel P (1980) Na+-Independent binding of [3H]GABA and [3H]muscimol to subcellular particles of neuronal primary cultures and whole brains. J Neurochem 34:216–218
Dray A, Gonye TJ, Oakley NR, Tanner T (1976) Evidence for the existence of a raphe projection to the substantia nigra in rat. Brain Res 113:45–57
Giambalvo CT, Snodgrass SR (1978) Biochemical and behavioral effects of serotonin neurotoxins on the nigrostriatal dopamine system: comparison of injection sites. Brain Res 152:555–566
Goldstein JM, Litwin LC, Sutton EB, Malick JB (1989) Effects of ICI169,369, a selective serotonin antagonist, in electrophysiological tests predictive of antipsychotic activity. J Pharmacol Ther 249:673–680
Gozlan H, El Mestikawy S, Pichat L, Glowinski J, Hamon M (1983) Identification of presynaptic serotonin autoreceptors using a new ligand:3H-PAT. Nature 305:140–142
Greengrass P, Bremner R (1979) Binding characteristics of [3H]prazosin to rat brain α-adrenergic receptors. Eur J Pharmacol 55:322–326
Herve DJ, Pickal UM, Joh TH, Beaudet A (1987) Serotonin axon terminals in the ventral tagmental area of the rat: same structure and synoptic input to dopaminergic neurons. Brain Res 435:71–83
Itzhak Y (1989) Multiple affinity binding slotes of the sigma receptor: effect of GTP-binding protein modifying agents. Mol Pharmacol 36:512–517
Kilpatrick GJ, Jones BJ, Tyers MB (1987) Identification and distribution of 5-HT3 receptors in rat brain using radioligand binding. Nature 330:746–748
Leysen JE, Niemegeurs CJR, van Heuten JM, Laduron PM (1982) [3H]Ketanserin (R41468), a selective3H-ligand for serotonin2 receptor binding sites. Mol Pharmacol 21:310–314
Meltzer HY (1989) Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:S18-S27
Meltzer HY, Matsubara S, Lee JC (1989) Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J Pharmacol Exp Ther 251:238–246
Minabe Y, Ashby CR, Wang RY (1991) The effect of acute and chronic LY 277359, a selective 5-HT3 receptor antagonist, on the number of spontaneously active midbrain dopamine neurons. Eur J Pharmacol 209:151–156
Minabe Y, Ashby CR, Wang RY (1992) Effects produced by acute and chronic treatment with granisetron alone or in combination with haloperidol on mid brain dopamine neurons. Eur Neuropsychopharmacol (in press)
Palfreyman MG, Sorensen SM, Carr AA, Cheng HC, Dudley MW (1991) 5-HT3 receptor antagonists and their potential in psychiatric disorders. In: Sandler M, Coppen A, Harnett S (eds) 5-Hydroxytryptamine in psychiatry: a spectrum of ideas. Oxford University Press, Oxford, pp 324–330
Palfreyman MG, Sorensen SM, Baron BM, Humphreys TM, Moser P, Dudley MW (1992) Antipsychotic potential of 5-HT3 antagonists. In: Meltzer HY (ed) Novel antipsychotic drugs. Raven Press, New York, pp 211–223
Pazos A, Hoyer D, Palacios JM (1984) The binding of serotonergic ligands to the porcine choroid plexus: characterization of a new type of serotonin recognition site. Eur J Pharmacol 106:546–589
Pazos A, Cortes R, Palacios J (1985) Autoradiographic mapping of serotonin receptors in the rat brain. II. Serotonin-2 receptors. Brain Res 346:231–249
Schmidt CJ (1987) Neurotoxicity of the psychedelic amphetamine, methylenedioxy-methamphetamine. J Pharmacol Exp Ther 240:1–7
Schmidt CJ, Black CK, Taylor VL (1990b) Antagonism of the neurotoxicity due to a single administration of methylenedioxy/methamphetamine. Eur J Pharmacol 181:59–70
Schmidt CJ, Taylor VL, Abbate GM, Nieduzak TR (1991a) 5-HT2 antagonists stereoselectively prevent the neurotoxicity of 3,4-methylenedioxy-methamphetamine by blocking the acute stimulation of dopamine synthesis: reversal byl-dopa. J Pharmacol Exp Ther 256:230–235
Schmidt CJ, Black CK, Taylor VL (1991b)l-Dopa-potentiation of the serotonergic deficits due to a single administration of 3,4 methylene dioxymethamphetamine,p-chloroamphetamine or methamphetamine to rats. Eur J Pharmacol 203:41–49
Schmidt CJ, Fadayel GM, Black CK, Taylor VL (1992a) 5-HT2 receptors exert a state-dependent regulation of dopaminergic function: studies with MDL 100,907 and the amphetamine analogue, 3,4-methylenedioxymethamphetamine.
Schmidt CJ, Black CK, Taylor VL, Fadayel GM, Humphreys TM, Nieduzak TR, Sorensen SM (1992b) The 5-HT2 antagonist, MDL 28,133A disrupts the serotonergic-dopaminergic interaction mediating the long-term neurochemical effects of 3,4-methylenedioxymethamphetamine.
Snyder SH, Chang KJ, Keehar MJ, Yamamura HI (1975) Biochemical identification of the mammalian muscarinic cholinergic receptor. Fed Proc 34:1915–1921
Sorensen SM, Humphreys TM, Palfreyman MG (1989) Effect of acute and chronic MDL 73,147EF, a 5HT3 antagonist, on A9 and A10 dopamine neurons. Eur J Pharmacol 163:115–118
Sorensen SM, Humphreys TM, Taylor VL, Schmidt CJ (1992) 5-HT2 antagonists reverse amphetamine-induced slowing of dopaminergic neurons by interfering with stimulated dopamine synthesis. J Pharmacol Exp Ther 260:872–878
Waeber C, Schoeffler P, Palacios JM, Hoyer D (1988) Molecular pharmacology of 5-HT1D recognition sites: radioligand binding studies in human, pig and calf brain membranes Naunyn-Schmiedeberg's Arch Pharmacol 337:595–601
Young AB, Snyder SH (1973) Strychnine binding associated with glycine receptors of the central nervous system. Proc Natl Acad Sci USA 70:2832–2836
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Palfreyman, M.G., Schmidt, C.J., Sorensen, S.M. et al. Electrophysiological, biochemical and behavioral evidence for 5-HT2 and 5-HT3 mediated control of dopaminergic function. Psychopharmacology 112 (Suppl 1), S60–S67 (1993). https://doi.org/10.1007/BF02245008
Issue Date:
DOI: https://doi.org/10.1007/BF02245008